Nautilus Biotechnology Inc
NASDAQ:NAUT

  • LAST PRICE
    2.5700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.4700/ 7
  • Ask / Lots
    2.6200/ 2
  • Open / Previous Close
    0.0000 / 2.5700
  • Day Range
    ---
  • 52 Week Range
    2.1600
    4.6500
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 1 hour ago by Dow Jones
      Companies Mentioned: NAUT

    • 1 hour ago by Dow Jones
      Companies Mentioned: NAUT
      Net loss $ (18,730) $ (14,965) ============ =========== Net loss per share attributable to common stockholders, basic and diluted $ (0.15) $ (0.12) ============ =========== Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 125,135,451 124,590,351 ============ =========== Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Cash Flows Three Months Ended March 31, 2024 and 2023 (Unaudited) Three Months Ended March 31, -------------------------------------- (in thousands) 2024 2023 ------------------- ----------------- Cash flows from operating activities Net loss $ (18,730) $ (14,965) Adjustments to reconcile net loss to net cash used in operating activities Stock-based compensation expense 3,114 2,860 Amortization of operating lease right-of-use assets 1,075 786 Depreciation 516 385 Amortization (accretion) of premium (discount) on securities, net (751) (669) Changes in operating assets and liabilities: Prepaid expenses and other assets (309) (513) Accounts payable 94 53 Accrued expenses and other liabilities (268) 65 Operating lease liabilities (1,007) (526) ----------- ---------- Net cash used in operating activities (16,266) (12,524) ----------- ---------- Cash flows from investing activities Proceeds from maturities of securities 23,000 14,249 Purchases of securities -- (27,052) Purchases of property and equipment (647) (692) ----------- ---------- Net cash provided by (used in) investing activities 22,353 (13,495) ----------- ---------- Cash flows from financing activities Proceeds from exercise of stock options 245 1 Net cash provided by financing activities 245 1 ----------- ---------- Net increase (decrease) in cash, cash equivalents and restricted cash 6,332 (26,018) Cash, cash equivalents and restricted cash at beginning of period 20,399 115,477 ----------- ---------- Cash, cash equivalents and restricted cash at end of period $ 26,731 $ 89,459 =========== ==========

  • Apr 11, 2024

Peers Headlines